Table 1.
The clinicopathologic features of patients with prostate cancer (n=167), and the correlations between PCDH17 methylation and these features.
| Features | Variables | No. | M (%) | U (%) | P |
|---|---|---|---|---|---|
| Age (years) | ≤70 | 89 | 48 (53.9) | 41 (46.1) | 0.410 |
| >70 | 78 | 47 (60.3) | 31 (39.7) | ||
| Preoperative PSA (ng/ml) | ≤10 | 64 | 29 (45.3) | 35 (54.7) | 0.017 |
| >10 | 103 | 66 (64.1) | 37 (35.9) | ||
| Pathologic stage | T1 | 85 | 43 (50.6) | 42 (49.4) | 0.033 |
| T2 | 57 | 32 (56.1) | 25 (43.9) | ||
| T3 | 25 | 20 (80.0) | 5 (20.0) | ||
| Gleason score | ≤6 | 43 | 19 (44.2) | 24 (55.8) | 0.025 |
| 7 | 72 | 39 (54.2) | 33 (45.8) | ||
| ≥8 | 52 | 37 (71.2) | 15 (28.8) | ||
| Lymph node status | N0 | 149 | 82 (55.0) | 67 (45.0) | 0.164 |
| N1 | 18 | 13 (72.2) | 5 (27.8) | ||
| Surgical margin status | Negative | 156 | 88 (59.1) | 68 (40.9) | 0.640 |
| Positive | 11 | 7 (63.6) | 4 (36.4) | ||
| Recurrence | No | 120 | 55 (45.8) | 65 (54.2) | <0.001 |
| Yes | 47 | 40 (85.1) | 7 (14.9) |
M – methylation; U – unmethylation.